UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of June 2024
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Form
20-F ☒ Form 40-F ☐
EXHIBIT INDEX
|
Exhibit No.
|
Description
of Exhibit
|
|
99.1
|
|
|
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Indivior PLC
|
|
Date: June 27, 2024
|
/s/
Kathryn Hudson
|
|
|
Name:
Kathryn Hudson
|
|
|
Title:
Company Secretary
|
Exhibit
99.1
Indivior PLC (the
"Company")
Indivior's primary listing now on the Nasdaq Stock
Market
June 27, 2024
The Company announces that its primary listing is now on the Nasdaq
Stock Market ("Nasdaq"). This follows the transfer of the Company's
listing category on the Official List of the U.K. Financial Conduct
Authority from "Premium Listing (commercial company)" to "Standard
Listing (shares)" as of 08.00 a.m. U.K. / 03.00 a.m. ET today. The
Company's shares remain eligible for and continue to trade on the
Main Market of the London Stock Exchange ("LSE") as a Standard
Listing segment issuer.
On February 22, 2024, the Board announced its intention to consult
with shareholders about the proposed relocation of the Company's
primary listing from the U.K. to the U.S. Having completed the
consultation, the Board announced on April 25, 2024 that, following
careful consideration of the feedback received, it had decided to
seek the approval of shareholders for the proposed transfer of its
primary listing. On May 23, 2024, shareholders passed the
special resolution to transfer the Company's listing category from
a Premium Listing to a Standard Listing on the LSE, which has taken
effect today. With immediate effect therefore, the Company's
primary listing is on Nasdaq.
Graham Hetherington, Chair, said:
"We are pleased to achieve this
key milestone for Indivior. A U.S. primary listing on Nasdaq best
reflects the profile of Indivior's business, which is focused on
growing its leadership position in the U.S. addiction treatment
market. We appreciate the strong support received from shareholders
for this initiative and look forward to capitalizing on the
expected benefits of this move, including greater investor
awareness of Indivior's leadership position in addiction treatment
and its opportunities for continued strong
growth."
Key
Contacts:
Jason Thompson
VP, Investor Relations
+1 804-402-7123 or jason.thompson@indivior.com
Tim Owens
Director, Investor Relations
+1 804-263-3978 or timothy.owens@indivior.com
Kathryn Hudson
Company Secretary
+44 (0)1753 423940 or kathryn.hudson@indivior.com
Indivior PLC's Legal Entity Identifier code is
213800V3NCQTY7IED471.
About Indivior
Indivior is a global pharmaceutical company
working to help change patients' lives by developing medicines to
treat substance use disorders (SUD) and serious mental illnesses.
Our vision is that all patients around the world will have access
to evidence-based treatment for the chronic conditions and
co-occurring disorders of SUD. Indivior is dedicated to
transforming SUD from a global human crisis to a recognized and
treated chronic disease. Building on its global portfolio of OUD
treatments, Indivior has a pipeline of product candidates designed
to both expand on its heritage in this category and potentially
address other chronic conditions and co-occurring disorders of SUD,
including alcohol use disorder and cannabis use disorder.
Headquartered in the United States in Richmond, VA,
Indivior employs over 1,100 individuals globally and its portfolio
of products is available in 37 countries worldwide.
Visit www.indivior.com to
learn more. Connect with Indivior on LinkedIn by
visiting www.linkedin.com/
company/indivior.
Important Cautionary Note Regarding Forward Looking
Statements
This presentation contains certain statements that are
forward-looking. Forward-looking statements include, among other
things, statements regarding future growth, the expected benefits
of a U.S. primary listing, and other statements containing the
words "believe," "anticipate," "plan," "expect," "intend,"
"estimate," "forecast," "strategy," "target," "guidance,"
"outlook," "potential," "project," "priority," "may," "will,"
"should," "would," "could," "can," "outlook," "guidance," the
negatives thereof, and variations thereon and similar expressions.
By their nature, forward-looking statements involve risks and
uncertainties as they relate to events or circumstances that
may or may not occur in the future.
Actual results may differ materially from those expressed or
implied in such statements. Various factors may cause differences
between Indivior's expectations and actual results, including,
among others, the risks
associated with the relocation of our primary listing to the US and
any volatility in our share price and shareholder base in
connection therewith; weakness in the economy, market trends,
uncertainty and other conditions in the markets in which we
operate, and other factors beyond our control, including any
macroeconomic or other consequences of the current armed conflicts;
our ability or inability to execute our strategic priorities; and
the risks set forth in our annual report on Form 20-F filed with
the Securities and Exchange Commission on March 6, 2024, under the
heading "Risk Factors."
Forward-looking statements speak only as of the date that they are
made and should be regarded solely as our current plans, estimates
and beliefs. Except as required by law, we do not undertake
and specifically decline any obligation to update, republish or
revise forward-looking statements to reflect future events or
circumstances or to reflect the occurrences of unanticipated
events.
Indivior (PK) (USOTC:IZQVF)
過去 株価チャート
から 5 2024 まで 6 2024
Indivior (PK) (USOTC:IZQVF)
過去 株価チャート
から 6 2023 まで 6 2024
